Alligator Bioscience AB is characterized by its core values of innovation, scientific excellence, and patient focus. With a strong corporate philosophy, Alligator Bioscience AB strives to improve the lives of patients by developing innovative antibody-based immunotherapies. The company is dedicated to conducting groundbreaking research, utilizing cutting-edge technologies, and collaborating with key stakeholders to address unmet medical needs in oncology. Alligator Bioscience AB emphasizes integrity, transparency, and teamwork in its pursuit of novel therapeutics that have the potential to make a significant impact on the treatment of cancer.

Alligator Bioscience AB is primarily present in Sweden.

Alligator Bioscience AB has achieved several significant milestones. The company successfully advanced its lead immune-oncology drug, ATOR-1017, into Phase I clinical trials. Additionally, Alligator Bioscience AB formed a strategic partnership with Aptevo Therapeutics to jointly develop and commercialize ALG.APV-527, a bispecific antibody-based immunotherapy. Furthermore, the company expanded its pipeline by initiating the preclinical development of ATOR-1015, another promising immune-oncology candidate. These accomplishments showcase Alligator Bioscience AB's dedication to advancing innovative therapies in the field of cancer treatment, solidifying its position as a notable player in the biotechnology sector.

Alligator Bioscience AB is a renowned Swedish biotechnology company specializing in the development of innovative antibody-based immunotherapies for cancer treatment. Founded in 2001, Alligator Bioscience has built a strong expertise in discovering and developing next-generation antibodies known as tumor-directed immunomodulators. With a focus on creating novel treatment options that harness the body's immune system to fight cancer, Alligator Bioscience has established itself as a key player in the biopharmaceutical industry. The company has forged strategic collaborations with several leading pharmaceutical companies and continues to drive advancements in cancer immunotherapy.

The main competitors of Alligator Bioscience AB in the market are biotechnology companies and pharmaceutical companies that focus on the development of novel immunotherapies and anticalins. Some notable competitors of Alligator Bioscience AB include Agenus Inc., argenx SE, Bavarian Nordic A/S, and Genmab A/S.

Alligator Bioscience AB primarily operates in the biotechnology and pharmaceutical industries.

The business model of Alligator Bioscience AB is focused on developing innovative antibody-based drugs to address unmet medical needs in cancer treatment. Alligator Bioscience utilizes its proprietary discovery platform, called the FIND technology, to identify potential drug candidates and enhance their effectiveness. By collaborating with leading pharmaceutical companies, Alligator Bioscience seeks to leverage its expertise and technologies to bring novel therapeutics to market. Through strategic partnerships and licensing agreements, the company aims to generate revenues and maximize shareholder value. Alligator Bioscience's business model centers on pioneering research and development efforts in the field of immuno-oncology to ultimately improve patients' lives.

Il P/E (Price/Earnings) di Alligator Bioscience è -4,79.

Il KUV di Alligator Bioscience è 2,29.

Il Quality Score AlleAktien per Alligator Bioscience è 4/10.

Il fatturato di attesa Alligator Bioscience è 245,14 Mio. SEK.

Il attesa Alligator Bioscience profitto è -117,12 Mio. SEK.

Alligator Bioscience AB is a Swedish company specializing in the research and development of antibodies and immuno-oncology. The company's business model focuses on creating customer-oriented solutions that contribute to improving patient health and the pharmaceutical industry. Alligator Bioscience offers two main categories of products: 1. Immuno-oncology products 2. Advanced immunostimulants Alligator Bioscience is particularly known for its immuno-oncology products, which are specifically designed to fight cancer. These products are based on blocking specific antibodies that allow cancer cells to invade healthy tissue. In doing so, Alligator Bioscience contributes to the development of new therapies that can effectively and rapidly combat cancer cells and improve patients' quality of life. Alligator Bioscience's advanced immunostimulants are based on combining antibodies and molecules (such as immune checkpoint modulators) to influence and control immune responses. These immunomodulating antibodies can be used for both cancer treatment and the treatment of autoimmune diseases. Alligator Bioscience follows an "open innovation" strategy, focusing on collaboration with partners from the pharmaceutical industry and academic institutions. This allows Alligator Bioscience to advance its research and development by leveraging the knowledge and resources of its strategic partners. The company also has a strong development and innovation department that is dedicated to advancing the discovery and development of new drugs and technologies. Alligator Bioscience continuously invests in supplementing its pipelines through collaborations, licensing agreements, and acquisitions. Alligator Bioscience has built a strong network of partners, including biotech and pharmaceutical companies that further develop and market the products and solutions of Alligator Bioscience. The company also collaborates with contract research organizations and other institutions in the science and technology field. Furthermore, Alligator Bioscience plans to expand into international markets to increase its revenue and global presence. With its strong focus on researching and developing new technologies and drugs, Alligator Bioscience is well-positioned to remain a leader in the industry and deliver new discoveries and products. Overall, Alligator Bioscience is an innovative company specializing in the research and development of new technologies and products in immuno-oncology. With its open innovation strategy, strong development and innovation department, and broad network of partners, Alligator Bioscience aims to revolutionize the field of cancer treatment through the development of innovative therapies.

Alligator Bioscience distribuisce un dividendo di 0 SEK suddiviso in pagamenti all'anno.

La dividendazione per Alligator Bioscience non può essere attualmente calcolata oppure la società non distribuisce dividendi.

La ISIN di Alligator Bioscience è SE0000767188.

Il codice WKN di Alligator Bioscience è A2AN1Z.

Il ticker di Alligator Bioscience è ATORX.ST.

Nell'ultimo anno, Alligator Bioscience ha pagato un dividendo di . Questo corrisponde a un rendimento da dividendo di circa . Per i prossimi 12 mesi, Alligator Bioscience prevede di pagare un dividendo di 0 SEK.

La resa dei dividendi di Alligator Bioscience è attualmente del .

Alligator Bioscience paga un dividendo su base trimestrale. Questo viene distribuito nei mesi di .

Alligator Bioscience ha pagato un dividendo ogni anno negli ultimi 0 anni.

Nei prossimi 12 mesi si prevedono dividendi per un importo di 0 SEK. Questo corrisponde a un rendimento da dividendo del 0 %.

Alligator Bioscience è assegnato al settore 'Salute'.

Per ricevere l'ultima dividend of Alligator Bioscience del 26/08/2024 dell'importo di 0 SEK, dovevi avere l'azione in portafoglio prima del giorno "Ex" il 26/08/2024.

La distribuzione dell'ultima dividenda è avvenuta il 26/08/2024.

Nell'anno 2023 sono stati distribuiti da Alligator Bioscience 0 SEK come dividendi.

Le dividende di Alligator Bioscience vengono distribuite in SEK.